A Phase II Study with Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer.
- Author:
Jae Wan PARK
1
;
Hwan Yang PARK
;
Yong Bae PARK
;
Jung Won KANG
;
Sung Hung KIM
;
Gwi Lae LEE
;
Bong Seog KIM
;
Yong Ho ROH
Author Information
1. Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea. seog@netsgo.com
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Combination chemotherapy;
Gemcitabine;
Carboplatin
- MeSH:
Adenocarcinoma;
Agranulocytosis;
Anemia;
Area Under Curve;
Carboplatin*;
Carcinoma, Non-Small-Cell Lung*;
Carcinoma, Squamous Cell;
Drug Therapy, Combination;
Humans;
Lung Neoplasms;
Male;
Recurrence;
Thrombocytopenia
- From:Cancer Research and Treatment
2002;34(1):23-27
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the efficacy and safety of gemcitabine and carboplatin (GC) in the treatment of advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Between November 1999 and April 2001, 34 patients were enrolled in this study. The median age was 66 (range: 52-74) years old and all were male. Sixteen patients demonstrated stage IIIB, 15 stage IV, and 3 recurrence of disease after surgery. Twenty-two patients showed a ECOG performance status of 0 or 1 and 12 had 2. Twenty patients presented with squamous cell carcinoma, 11 adenocarcinoma and 3 unclassified NSCLC. The treatment regimen consisted of intravenous carboplatin AUC of 6 on day 1 and gemcitabine 1,250 mg/m2 on day 1 and 8. The treatment was repeated every 28 days. Toxicities were evaluated according to WHO toxicity criteria. RESULTS: All thirty-four patients were evaluable. Partia responses were observed in 15 patients. The overall response rate was 44% (95% confidence interval: 27-61%) and the median response duration was 26 (range 8-60 ) weeks. The median survival of all patients was 50 (range 8-70 ) weeks. During a total of 144 cycles, granulocytopenia greater than WHO grade 2 occurred in 2%, thrombocytopenia in 2%, and anemia in 3%, respectively. Non- hematologic toxicities were minor and easily controlled. CONCLUSION: A combination chemotherapy of intravenous gemcitabine and carboplatin has a relatively high activity with acceptable toxicities in patients with advanced NSCLC.
